WHO decides to resume hydroxychloroquine anti-new coronavirus trial

Following a temporary suspension of the hydrochloroquine anti-new coronavirus trial on 25 May, WHO announced on The 3rd that, based on available patient mortality data, WHO decided to resume the hydrochloroquine anti-new coronavirus trial. WHO Director-General Tan Desai said at a regular press conference at WHO headquarters in Geneva on the same day, out of concern for drug safety, the WHO “Solidarity Pilot Project” implementation team decided to temporarily stop the hydroxchloroquine anti-new coronavirus test, the safety data monitoring committee has been evaluating oxychloroquine safety data, “based on existing disease mortality data, members of the Committee recommended no reason to modify the pilot program.”

WHO decides to resume hydroxychloroquine anti-new coronavirus trial

Tandeser said that the WHO Solidarity Pilot Project Implementation Group had accepted the advice of the Safety Data Monitoring Committee and agreed to continue the work of all branches of the Solidarity Pilot Project, including the hydroxychloroquine anti-new coronavirus trial, and that the implementation team would later communicate with the relevant research leaders on the resumption of oxychloroquine anti-new coronavirus tests.

In March, WHO launched the Solidarity Pilot Project to compare the safety and efficacy of four anti-new coronavirus drugs or combinations through clinical trials, with hydroxychloroquine, an antimalarial drug, not among them( an observational study published in the Lancet, a leading medical journal, on May 22, showed that patients with new coronary pneumonia, whether they took chloroquine or chloroquine alone, were more likely to be given in combination with the large stequins.

Public doubts about hydroxychloroquine were high after WHO’s announcement on 25 May that it had suspended the trial of oxychloroquine against neo-coronaviruses, although there were also voices that thought the observational study published in The Lancet was flawed and that its research methods and data collection did not reflect the actual situation.

As to the “pharmacological effect” of hydroxychloroquine, WHO Chief Scientist Swaminathan stressed at a press conference on the 3rd that there are still many “unknowns” in the use of hydroxychloroquine to treat new coronapneumonia, only through clinical trials, especially the standard randomized trials can be given the exact answer, so WHO encourages the continuation of hydroxychloroquine anti-new coronavirus tests, while closely monitoring the test safety data, the future does not rule out the trial adjustment. (China News Agency, Brussels, June 3rd)

WHO decides to resume hydroxychloroquine anti-new coronavirus trial